罗沙司他治疗腹膜透析患者贫血的多中心、回顾性、自身对照研究北大核心CSCD

目的观察罗沙司他治疗腹膜透析患者贫血的疗效。方法收集2019年11月1日至2021年6月30日中国医科大学附属第一医院、沈阳市红十字会医院、北部战区总医院、鞍钢集团总医院4家腹膜透析中心规律随访伴肾性贫血应用罗沙司他的腹膜透析患者数据。采取前后自身对照设计,回顾分析应用罗沙司他前后患者贫血的治疗效果。结果共纳入长期腹膜透析伴肾性贫血应用罗沙司他的患者113例。用药前血红蛋白(hemoglobin,Hb)为(81.9±13.9)g/L,应用罗沙司他至1、2、3个月时Hb分别为(97.6±18.4)、(105.5±20.4)、(110.6±16.6)g/L。随访结束前最后一次复查Hb为(104.8±19.2)g/L。用药至1个月时91.2%患者(103/113例)Hb呈不同程度的升高达(20.1±13.9)g/L(2~58 g/L)。应用罗沙司他1~3月后血清铁、转铁蛋白、转铁蛋白饱和度升高;血清铁蛋白、三酰甘油、总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇降低。结论罗沙司他有效改善腹膜透析患者贫血,改善铁利用,降低血脂。

A multi-center,retrospective,self-controlled study of Roxadustat in treatment of anemia in peritoneal dialysis patients

Objective To observe the efficacy of Roxadustat in the treatment of anemia in peritoneal dialysis patients.Methods The data of peritoneal dialysis patients with renal anemia treated with Roxadustat in the First Affiliated Hospitalof China Medical University,Shenyang Red Cross Hospital,General Hospital of Northern Theater Command and AnsteelGroup General Hospital from November 1,2019 to June 30,2021 were collected.The Roxadustat’s efficacy on anemia inperitoneal dialysis patients was retrospectively analyzed through a before-and-after self-controlled design.Results Thedata of a total of 113 patients were recorded.The hemoglobin(Hb)before Roxadustat medication was(81.9±13.9)g/L,andthe Hb was(97.6±18.4),(105.5±20.4)and(110.6±16.6)g/L at 1,2,and 3 months afer medication.The Hb of the latestreexamination was(104.8±19.2)g/L.About 91.2% of the patients(103/113 cases)had a different degree of increase in Hb,which was up to(20.1±13.9)g/L(2-58 g/L)at the end of the first month.Serum iron,transferrin,and transferrinsaturation increased after using Roxadustat for 1-3 months,while serum ferritin,triglycerides,total cholesterol,low-density lipoprotein cholesterol,and high-density lipoprotein cholesterol decreased.Conclusion Roxadustat is effective inimproving anemia and iron utilization and reducing blood lipid in peritoneal dialysis patients.